FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) reported that Novartis Pharma AG and its development partner Nordic Bioscience have initiated a multi-center Phase III clinical study to evaluate the use of their oral formulation of calcitonin to treat osteoarthritis. The calcitonin to be used in the study was produced by Novartis using Unigene’s patented manufacturing process, and Unigene will receive royalty payments if the product is successfully commercialized using this calcitonin.
